Cancer Clinical Trial
Official title:
Trial of a Smartphone Application to Improve Medication Adherence Among Patients With Cancer
For this current proposal, the investigator will conduct a single-center prospective non-randomized pilot interventional study in patients with any stage and type of cancer who are either taking at least one OACD or are taking at least one oral medication for chronic condition management in conjunction with any cancer treatment. Primary Objective: To determine the feasibility of using a medication reminder application (Medisafe App) to improve medication adherence in cancer patients either receiving oral anticancer agents (OACDs) or receiving oral medications for chronic disease management (non-OACDs) in conjunction with non-oral cancer treatment. Secondary Objectives: To compare and characterize medication adherence before and after the 12-week intervention using the Voils Extent of Adherence Scale and the Medisafe App. Also to determine the acceptability, utility and patient engagement with the App, to evaluate changes in healthcare related quality of life before and after the intervention, and to explore behaviors, knowledge, attitudes and beliefs related to medication adherence using a semi-structured interview delivered over the telephone.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | April 15, 2024 |
Est. primary completion date | April 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Any type/stage cancer - Patients must be taking either: - at least one oral anti-cancer drug (OACD) or - at least one oral medication (non-OACD) for management of a chronic condition in addition to receiving non-oral cancer treatment - Patients must have access to a mobile phone or tablet that can download the Medisafe App. (ie apple/android) - Subjects must be able to complete self-administered questionnaires in English or Spanish. - Co-enrollment in trials involving pharmacologic therapy is allowed. Exclusion Criteria: - Inability to provide informed consent |
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Irving Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Columbia University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects enrolled that complete the 12-week intervention and assessments | To determine the feasibility of using a medication reminder application (Medisafe App) to improve medication adherence in cancer patients. Feasibility defined as completing the 12-week intervention and the endpoint assessments. Patients will be tallied. | 12 weeks | |
Secondary | Change in mean score on the Voils Extent of Adherence Scale for oral caner therapy use between baseline and 12 weeks | To compare medical adherence to OACDs before and after the 12-week intervention using the Voils Extent of Adherence Scale for OACD use. The Extent of Adherence subscale of the Voils Self-Reported Medication Nonadherence Measurement (Voils Measure) will be used for self-assessment of drug adherence. The Extent of Adherence subscale of the Voils Measure consists of three questions with responses ranging from 1 (perfect adherence) to 5 (highest degree of nonadherence). The Extent score can be calculated in two different ways: the three items in the Extent scale can be averaged, with higher scores representing greater nonadherence, or the scale can be dichotomized, such that perfect adherence is considered "adherent", and any degree of nonadherence is considered "nonadherent." | Baseline and 12 weeks | |
Secondary | Change in mean score on the Voils Extent of Adherence Scale for global medication use between baseline and 12 weeks | To compare medical adherence to OACDs before and after the 12-week intervention using the Voils Extent of Adherence Scale for OACD use. The Extent of Adherence subscale of the Voils Self-Reported Medication Nonadherence Measurement (Voils Measure) will be used for self-assessment of drug adherence. The Extent of Adherence subscale of the Voils Measure consists of three questions with responses ranging from 1 (perfect adherence) to 5 (highest degree of nonadherence). The Extent score can be calculated in two different ways: the three items in the Extent scale can be averaged, with higher scores representing greater nonadherence, or the scale can be dichotomized, such that perfect adherence is considered "adherent", and any degree of nonadherence is considered "nonadherent." For this study, global adherence will be defined as a perfect score (1) for each medication. | Baseline and 12 weeks | |
Secondary | Mean Score to Medication Self-Efficacy Scale (MASES) to assess a patient's confidence in their ability to take their medications in a variety of situations | The Medication Self-Efficacy Scale (MASES) is a tool used to assess a patient's confidence in their ability to take their medications in a variety of situations. This is a 25-item scale and items are scored 1= not sure at all, to 4= very sure, and the total scores of the measure is the mean response to all the items (range 1-4). | 12 weeks | |
Secondary | Mean Score on the User Version of the Mobile Application Rating Scale | The User Version of the Mobile Application Rating Scale (uMARS) is a 20-item tool used for classifying and assessing the quality of mobile health apps. It contains four objective quality subscales including engagement, functionality, aesthetics, and information quality. Each of the 20-items have an outcome of 1-5; the overall outcome scale ranges from 20-100. It has been developed and validated specifically for end user administration. | 12 weeks | |
Secondary | Change in Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Score before and after the intervention | The Patient-Reported Outcomes Measurement Information System (PROMIS) 29 is a well- validated assessment tool that offers both qualitative and quantitative measures of health-related quality of life. The PROMIS-29 includes 29 questions evaluating areas of physical function, anxiety, depression, fatigue, sleep, social functioning, and pain interference. The PROMIS-29 assesses severity levels of symptoms and their effect on the patient's functioning. | Baseline and 12 weeks | |
Secondary | Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Domain Score before and after the intervention | The 14-item TSQM Version 1.4 is a reliable and valid instrument to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction. We will use the validated abbreviated TSQM-9.24 This questionnaire includes 9-items that address six different domains which include domains of TS-M included; (1) side effects, (2) symptom relief, (3) convenience, (4) effectiveness, (5) impact on daily life, and (6) tolerability/acceptability. Scoring of the TSQM-9 provides a domain score that ranges from 0- 100 with higher scores representing higher satisfaction on each domain. | Baseline and 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|